Skip to main
ICLR
ICLR logo

ICON (ICLR) Stock Forecast & Price Target

ICON (ICLR) Analyst Ratings

Based on 25 analyst ratings
Buy
Strong Buy 32%
Buy 24%
Hold 44%
Sell 0%
Strong Sell 0%

Bulls say

Icon's positive outlook is supported by its strategic positioning as a leading global late-stage contract research organization, particularly in a growing market characterized by increased pharmaceutical outsourcing and expanding R&D budgets. The successful acquisition of PRA has enhanced Icon's operational capabilities and allowed it to meet financial targets ahead of schedule, positioning the company well for future growth amid uncertain funding environments. Additionally, Icon's commitment to diversity and gender parity among leadership reflects a progressive company culture that may contribute to its competitive advantage in attracting talent and fostering innovation.

Bears say

Icon's stock outlook appears negative due to several fundamental concerns, including a reported book-to-bill ratio of 0.99 for a key competitor, Medpace, indicating demand challenges within the biotech-focused contract research organization sector. Furthermore, the anticipated earnings per share (EPS) for 2025 is projected to remain flat at the midpoints, highlighting stagnation amidst an environment of expected volatility and slower-than-anticipated recovery within the biotech industry. Additionally, a declining growth forecast, with an implied range of -2.8% to +4.5%, suggests ongoing revenue pressures that could lead to both reduced earnings and potential multiple compression moving forward.

ICON (ICLR) has been analyzed by 25 analysts, with a consensus rating of Buy. 32% of analysts recommend a Strong Buy, 24% recommend Buy, 44% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ICON (ICLR) Forecast

Analysts have given ICON (ICLR) a Buy based on their latest research and market trends.

According to 25 analysts, ICON (ICLR) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $197.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $197.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ICON (ICLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.